Quanterix Corporation IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Quanterix Corporation | QTRX - NASDAQ |
$14.00-$16.00 | $15.00 | $16.25 | 4.28 million | 12/7/2017 |
| J.P. Morgan, Leerink, Cowen | ||||||
Co-Manager(s): BTIG, Evercore ISI | ||||||
| Health Care | ||||||
Filing(s): Filed 2017-11-09 Terms Added 2017-11-27 Final Prospectus 2017-12-07 | ||||||
Quanterix Corporation Quote & Chart - Click for current quote - QTRX
IPO Boutique aggregates information on public companies and private companies, such as "QTRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Quanterix Corporation (adapted from Quanterix Corporation prospectus):
They are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "QTRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.